Intercure (INCR) vs PDS Biotechnology (PDSB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PDS Biotechnology (PDSB) has outperformed Intercure (INCR) over the past year, gaining 2.0% versus a loss of 37.5%. Over five years, INCR leads with a -85.8% price change compared with -91.7% for PDSB. Intercure is the larger company by market cap ($75.5 million vs $73.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | PDSB |
|---|---|---|
| Share price | $5.03 | $1.02 |
| Market cap | $75.47M | $73.92M |
| 1-day change | -1.95% | 0.00% |
| YTD return | +10.55% | +32.47% |
| 1-year return | -37.52% | +2.00% |
| 5-year return | -85.81% | -91.73% |
| EPS (TTM) | $-0.95 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $1.55 |
| 52-week low | $3.40 | $0.195 |
| Distance from 52-week high | -40.12% | -34.19% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +390.20% |
| Average volume | 21.73K | 23.24M |
| Shares outstanding | 15.00M | 72.47M |
| Employees | 285 | 21 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PDSB has outperformed INCR by 39.5 percentage points over the past year.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About PDS Biotechnology
PDSB stock →PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
INCR vs PDSB FAQ
Which is bigger, Intercure or PDS Biotechnology?
Intercure (INCR) is larger, with a market capitalization of $75.47M compared with $73.92M for PDS Biotechnology (PDSB).
Which stock has performed better over the past year, INCR or PDSB?
PDSB returned +2.00% over the past 12 months, compared with -37.52% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and PDS Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.